Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis

Vulvovaginal Candidiasis, Genital Clinical Trial

Official title:
Efficacy and Safety of Vaginal Suppositories Containing Combination of Natamycin and Lactulose in Treatment of Vulvovaginal Candidiasis: International, Randomized, Controlled, Superiority Clinical Trial

Status Completed

Clinical Trial Summary

The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg vaginal suppositories. The second objective of the study was to investigate the safety of the combination suppositories in the treatment of vulvovaginal candidiasis in non-pregnant adult females.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Candidiasis
Candidiasis, Vulvovaginal
Vulvovaginal Candidiasis, Genital

Clinical Trial Details

NCT number	NCT06411314
Study type	Interventional
Source	Avva Rus, JSC
Contact
Status	Completed
Phase	Phase 3
Start date	December 29, 2022
Completion date	September 22, 2023

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05273333` - Effect of Ultra-gyn® on Vulvovaginal Candidiasis	N/A
	Recruiting	`NCT04292704` - A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis	N/A